This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hosain, S. A. Articles by Chutorian, A. Search for Related Content PubMed PubMed Citation Articles by Hosain, S. A. Articles by Chutorian, A. Social Bookmarking                         What's this?

Topiramate for the Treatment of Infantile Spasms

Division of Pediatric Neurology, New York Presbyterian Hospital, Weill Medical College of Cornell University, sahosain{at}med.cornell.edu, Department of Pediatric Neurology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY

Sabiha Merchant, MD

Division of Pediatric Neurology, New York Presbyterian Hospital, Weill Medical College of Cornell University, Department of Pediatric Neurology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY

Gail E. Solomon, MD

Division of Pediatric Neurology, New York Presbyterian Hospital, Weill Medical College of Cornell University, Department of Pediatric Neurology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY

Abe Chutorian, MD

Division of Pediatric Neurology, New York Presbyterian Hospital, Weill Medical College of Cornell University, Department of Pediatric Neurology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY

Topiramate is a new antiepileptic drug with a broad spectrum of efficacy. Reports on the use of topiramate for treatment of infantile spasms are limited. We prospectively followed 15 children with recently diagnosed infantile spasms treated with topiramate for efficacy and tolerability. Twelve patients had symptomatic infantile spasms, and two patients had cryptogenic infantile spasms. Topiramate was started at a dose of 3 mg/kg/day and titrated up to a dose of 27 mg/kg/day in 2 to 3 weeks. The primary efficacy measure was comparison of the seizure rate during the 2-week baseline with the median seizure rate during the first 2 months of treatment with topiramate. We also compared baseline electroencephalograms (EEGs) with post-treatment EEGs. The median seizure rate reduction during the first 2 months of treatment was 41% (P = .002). Three patients became spasm free (20%), five had > 50% reduction, and three had at least 25% reduction. Four patients did not respond. Three of 15 patients had clearing of hypsarrhythmia. Topiramate was generally well tolerated, with irritability being the most common side effect. Topiramate was efficacious and well tolerated; one patient discontinued the medication because of adverse effects. (J Child Neurol 2006;21:17—19).

Journal of Child Neurology, Vol. 21, No. 1, 17-19 (2006)
DOI: 10.1177/08830738060210011001


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. Peltzer, W. D. Alonso, and B. E. Porter Topiramate and Adrenocorticotropic Hormone (ACTH) as Initial Treatment for Infantile Spasms J Child Neurol, April 1, 2009; 24(4): 400 - 405. [Abstract] [PDF]